Phase 1 tests whether a drug is safe, Phase 2 looks for early signs it works and refines the dose, and Phase 3 confirms it works in a large population. Each phase is bigger, longer, and more expensive than the last, and most drugs that start the journey never finish it. Here is what actually happens at each stage, and why the phases matter so much to patients, companies, and investors alike.
Before the phases: preclinical work
Long before a drug reaches a human, it goes through preclinical testing: laboratory and animal studies that establish how the drug behaves, whether it looks promising, and whether it is safe enough to try in people. Only after this work, and after the company files and clears an Investigational New Drug application with regulators, can clinical trials begin. Everything below happens on the human side of that line.
Phase 1: is it safe?
The first time a drug enters humans, the central question is safety, not whether it cures anything. Phase 1 trials are small, typically a few dozen participants, often healthy volunteers (though in areas like oncology they are usually patients, because giving a toxic cancer drug to healthy people would be unethical). Researchers start at low doses and cautiously increase them, watching closely for side effects and learning how the body absorbs, processes, and clears the drug. The goals are to establish a safe dose range and to characterize the drug’s basic behavior. A drug can look scientifically beautiful and still fail here if it turns out to be unsafe or intolerable. Phase 1 is relatively quick, but it is a real filter.
Phase 2: does it do anything?
Once a drug clears the safety bar, Phase 2 asks whether it actually works, and at what dose. These trials are larger, usually a few hundred patients who have the disease the drug is meant to treat, and they are designed to look for the first real signals of efficacy while continuing to monitor safety. Phase 2 is often where a drug’s dose is dialed in, testing different amounts to find the sweet spot between effect and side effects. This is also, statistically, where the most drugs die. Plenty of compounds that were safe in Phase 1 simply do not show enough benefit in Phase 2, and the program ends. Because it is the stage where the core hypothesis, does this drug help patients, gets its first serious test, Phase 2 results are among the most closely watched events in the industry.
Phase 3: does it work, convincingly?
A drug that shows promise in Phase 2 moves to Phase 3, the large, rigorous, expensive trials meant to prove safety and efficacy beyond reasonable doubt. These studies can enroll hundreds to thousands of patients across many sites, and often many countries, and they usually compare the new drug against either a placebo or the current standard of care. Phase 3 is the pivotal stage: its results are what regulators rely on to decide whether to approve the drug. Because they are so large and long, Phase 3 trials are enormously costly, often the single biggest expense in a drug’s development, which is why a Phase 3 failure is so financially devastating. Success here is what a company files with regulators in its marketing application.
The phases at a glance
| Phase | Main question | Typical size | Focus |
|---|---|---|---|
| Phase 1 | Is it safe? | Tens of participants | Safety, dose range, drug behavior |
| Phase 2 | Does it work at all? | Around 100 to 300 patients | Early efficacy, dose refinement, safety |
| Phase 3 | Does it work, convincingly? | Hundreds to thousands | Confirmatory efficacy and safety |
What happens after Phase 3
Positive Phase 3 data lets a company file its New Drug Application or Biologics License Application seeking approval to market the drug. If approved, the story is not quite over: Phase 4 studies, conducted after a drug is on the market, track its long-term safety and effectiveness in the real world, sometimes uncovering rare side effects that only appear once large numbers of people take the drug. You may also occasionally hear about Phase 0, small exploratory studies using tiny doses to gather very early human data before a full Phase 1; these are optional and relatively uncommon.
Why so many drugs fail
The single most important thing to understand about this system is how brutal it is. The large majority of drugs that enter clinical trials never reach the market; only a small fraction make it all the way through. Attrition happens at every stage, but the combination of Phase 2 (where efficacy is first truly tested) and Phase 3 (where it must be confirmed at scale) accounts for most of the heartbreak. This high failure rate is why drug development is so expensive, the successes have to pay for all the failures, and why each phase a drug clears makes it meaningfully more valuable. It is also why investors and executives treat phase transitions as major events: each one is a real reduction in risk.
Why the phases matter to you
Whether you are a patient considering a trial, an investor weighing a company, or a professional entering the field, the phase of a drug tells you almost everything about where it sits on the long road to approval and how much risk remains. A Phase 1 asset is exciting but deeply unproven; a drug with strong Phase 3 data is close to the finish line. Learning to read the phases is one of the most useful literacies in all of biotech, because so much of the industry’s news, and so much of its value, turns on which phase a drug just entered, or just failed.
How long the whole journey takes
Stacking the phases end to end explains why bringing a drug to market is measured in years, not months. Preclinical work alone can run several years before a drug is ready for humans. Phase 1 typically takes a year or so, Phase 2 often a couple of years, and Phase 3, with its large patient numbers and long follow-up, can stretch several years more. Then the regulatory review adds most of another year. Add it all up and the path from a promising molecule to an approved medicine commonly spans a decade or more, which, combined with the high failure rate, is why developing a single successful drug is so extraordinarily expensive. Every year of that timeline is also a year of spending with no revenue, which is why biotech companies live or die by their runway and why the timing of trials is inseparable from the timing of fundraising.
This is also why phase transitions function as the industry’s heartbeat. Each time a drug moves from one phase to the next, it has cleared a real hurdle and become meaningfully less risky, and the market reprices the company accordingly. A positive Phase 2 readout can transform a small biotech’s prospects overnight; a Phase 3 failure can erase most of its value just as fast. For investors, executives, and anyone following the field, learning to read where a drug sits in this sequence, and what its next readout will test, is one of the most useful skills in all of biotech, because so much of the industry’s news and value turns on exactly these transitions.
For daily coverage of the trial readouts and phase transitions that move companies and markets, the BioMed Nexus brief tracks them as they happen, and the clinical trial technology directory lists the platforms and providers that help sponsors run these studies faster and more reliably.
Frequently asked questions
What is the difference between Phase 1, 2 and 3 clinical trials?
Phase 1 tests a drug's safety and dose in a small group, often healthy volunteers. Phase 2 looks for early signs the drug works and refines the dose in a few hundred patients. Phase 3 is a large, pivotal trial in hundreds to thousands of patients that confirms safety and efficacy and forms the basis for approval.
How many patients are in each clinical trial phase?
Phase 1 typically involves tens of participants, Phase 2 usually around 100 to 300 patients, and Phase 3 hundreds to thousands across many sites. Each phase is progressively larger, longer and more expensive, with Phase 3 usually the biggest single cost in developing a drug.
Why do most drugs fail in clinical trials?
The large majority of drugs entering clinical trials never reach the market. Many are safe in Phase 1 but show too little benefit in Phase 2, and others fail to confirm efficacy at scale in Phase 3. This high attrition is why drug development is so costly and why each phase a drug clears makes it more valuable.
